Chronic myeloid leukemia: Overview of new agents and comparative analysis

Keyphrases

• New Agents 100%
• Comparative Analysis 100%
• Chronic Myeloid Leukemia 100%
• Agent Analysis 100%
• Tyrosine Kinase Inhibitor 54%
• Imatinib 18%
• Second-generation Tyrosine Kinase Inhibitors 18%
• Resistant Cases 18%
• Clinical Trials 9%
• Mechanism of Action 9%
• Age-matched 9%
• Popular 9%
• Tolerability 9%
• Loss of Response 9%
• Drug Resistance 9%
• Randomized Controlled Trial 9%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 9%
• Oncology 9%
• Novel Agents 9%
• Patient Compliance 9%
• Pharmacological Agents 9%
• Early Identification 9%
• New Drugs 9%
• Dasatinib 9%
• Adherence to Therapy 9%
• Ponatinib 9%
• Life Expectancy 9%
• Community Practice 9%
• Nilotinib 9%
• Resistance Loss 9%
• Frontline Therapy 9%
• Blast Phase 9%
• Chronic Myelogenous Leukemia Cells 9%
• Accelerated Phase 9%
• BCR-ABL Fusion Gene 9%
• T315I mutation 9%
• Kinase Domain mutations 9%
• Omacetaxine 9%
• Inhibitor Agent 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Myeloid Leukemia 100%
• Protein Tyrosine Kinase Inhibitor 66%
• Imatinib 16%
• Clinical Trial 8%
• Phosphotransferase 8%
• Tolerability 8%
• Drug Resistance 8%
• Randomized Controlled Trial 8%
• Dasatinib 8%
• Life Expectancy 8%
• Ponatinib 8%
• Nilotinib 8%
• BCR ABL Protein 8%